pharma

Moderna and Merck announced positive Phase 3 results for intismeran autogene, an mRNA-based individualized neoantigen therapy, in adjuvant treatment for melanoma.

Trump's executive order pushes splitting the MMR vaccine into separate shots, a move that pharmaceutical groups and medical experts sharply criticize as unscientific and dangerous. The industry says it would require costly development of vaccines that don't exist, with no evidence to justify the change.

GSK expands its $110M AI drug discovery partnership with Relation Therapeutics, emphasizing that clean, disease-specific biological data from lab experiments is more valuable than larger models. The move highlights an industry-wide pivot toward proprietary data as a competitive moat in AI-driven pharma.

AstraZeneca uses AI to generate and rank protein candidates, integrating models with experiments and robotics to speed up biologic drug discovery and tackle previously undruggable targets.

In this tweet, @sreeramkannan argues that AI labs will sell products of intelligence, not intelligence itself, with scientific inventions and entrepreneurship being the most valuable outputs. He references Anthropic's launch of Claude Science for pharma revenue as an example.

Derek Thompson highlights recent medical breakthroughs including an effective GLP-1 drug from Eli Lilly and a promising new pancreatic cancer drug from Revolution Medicines.

US biotech is in crisis as China surpasses the US in blockbuster pharma deals; the next FDA Commissioner must overhaul the agency and beat China to unleash cures.

Abinitio Bio launches foundation models for biomanufacturing that can turn 6-18 month process decisions into hours of compute, saving pharma $100M+ per month of delay. Their first model, Echo, predicts manufacturing outcomes more accurately than standard models.